← All indications
Nephrotic Syndrome
A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.
Drugs by status
Approved for this indication (16)
Phase 4 trials (10)
Phase 2 trials (13)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (32)
- Astellas
- Mallinckrodt
- Chong Kun Dang Pharmaceutical
- National Institutes of Health (NIH)
- Huazhong University of Science and Technology
- Aarhus University
- Central South University
- Arizona Kidney Disease and Hypertension Center
- University of London
- Nanjing Medical University
- Nilratan Sircar Medical College
- Northwell Health
- Rhode Island Hospital
- Seoul National University
- University of Leicester
- University of Tehran
- University of Athens
- Columbia University
- Fudan University
- Peking University
- Southeast Renal Research Institute
- Tel Aviv University
- Zhejiang University
- Shandong University
- Zhongshan Medical University
- University of Minnesota
- University of Lyon
- The University of Hong Kong
- Shantou University
- Shiraz University
- +2 more
Organization Involved with Phase 3 Indications (36)
- Genentech
- Novartis
- Bellus Health Inc
- Emory University
- Guangxi Medical University
- Guangzhou Medical University
- Ohio State University
- Radboud University
- Sichuan University
- University of Heidelberg
- University of Michigan
- University of Alberta
- Wenzhou Medical University
- All India Institute of Medical Sciences
- Tsinghua University
- Food and Drug Administration
- Jiao Tong University
- University of Limoges
- Southern Medical University
- National University of Singapore
- National Taiwan University
- Sun Yat-Sen University
- Mario Negri Institute
- Asahi Kasei Pharma
- Free University of Brussels
- University of Genoa
- 1st People's Hospital of Foshan
- University of Paris
- Agenzia Italiana del Farmaco
- NephCure Accelerating Cures Institute
- +6 more
Organization Involved with Phase 2 Indications (8)
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (9)